Archives of Clinical Infectious Diseases

Published by: Kowsar

Comparison of E Test and Disc Diffusion Methods for Susceptibility Testing of Filamentous Fungi; Experience of a Routine Lab

Reem Mostafa Hassan 1 , * , Dalia Kadry Ismail 1 and Yasmine Samy Elkholy 2
Authors Information
1 Department of Clinical and Chemical Pathology, Faculty of Medicine, Cairo University, Cairo, Egypt
2 Department of Medical Microbiology and Immunology, Faculty of Medicine, Cairo University, Cairo, Egypt
Article information
  • Archives of Clinical Infectious Diseases: June 2018, 13 (3); e57889
  • Published Online: June 29, 2018
  • Article Type: Research Article
  • Received: December 11, 2016
  • Revised: July 9, 2017
  • Accepted: September 19, 2017
  • DOI: 10.5812/archcid.57889

To Cite: Hassan R M, Kadry Ismail D, Samy Elkholy Y. Comparison of E Test and Disc Diffusion Methods for Susceptibility Testing of Filamentous Fungi; Experience of a Routine Lab, Arch Clin Infect Dis. 2018 ; 13(3):e57889. doi: 10.5812/archcid.57889.

Abstract
Copyright © 2018, Archives of Clinical Infectious Diseases. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited
1. Background
2. Methods:
3. Results
4. Discussion
Footnote
References
  • 1. Marr KA. Fungal infections in oncology patients: update on epidemiology, prevention, and treatment. Curr Opin Oncol. 2010;22(2):138-42. doi: 10.1097/CCO.0b013e328335a755. [PubMed: 20019613].
  • 2. Baddley JW, Marr KA, Andes DR, Walsh TJ, Kauffman CA, Kontoyiannis DP, et al. Patterns of susceptibility of Aspergillus isolates recovered from patients enrolled in the Transplant-Associated Infection Surveillance Network. J Clin Microbiol. 2009;47(10):3271-5. doi: 10.1128/JCM.00854-09. [PubMed: 19692558]. [PubMed Central: PMC2756905].
  • 3. Clinical and Laboratory Standards Institute (formerly NCCLS). Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi, approved standard. Wayne; 2008.
  • 4. Gupta P, Khare V, Kumar D, Ahmad A, Banerjee G, Singh M. Comparative Evaluation of Disc Diffusion and E-test with Broth Micro-dilution in Susceptibility testing of Amphotericin B, Voriconazole and Caspofungin against Clinical Aspergillus isolates. J Clin Diagn Res. 2015;9(1):DC04-7. doi: 10.7860/JCDR/2015/10467.5395. [PubMed: 25737984]. [PubMed Central: PMC4347075].
  • 5. Hoffman HL, Pfaller MA. In vitro antifungal susceptibility testing. Pharmacotherapy. 2001;21(8 Pt 2):111S-23S. [PubMed: 11501985].
  • 6. Clinical and Laboratory Standards Institute. Reference method for antifungal disk diffusion susceptibility testing of non-dermatophyte filamentous fungi; approved guideline. Villanova: CLSI document M51-A; 2010.
  • 7. Pfaller MA, Messer SA, Mills K, Bolmstrom A. In vitro susceptibility testing of filamentous fungi: comparison of Etest and reference microdilution methods for determining itraconazole MICs. J Clin Microbiol. 2000;38(9):3359-61. [PubMed: 10970383]. [PubMed Central: PMC87386].
  • 8. Colosi IA, Faure O, Dessaigne B, Bourdon C, Lebeau B, Colosi HA, et al. Susceptibility of 100 filamentous fungi: comparison of two diffusion methods, Neo-Sensitabs and E-test, for amphotericin B, caspofungin, itraconazole, voriconazole and posaconazole. Med Mycol. 2012;50(4):378-85. doi: 10.3109/13693786.2011.616543. [PubMed: 21981028].
  • 9. Espinel-Ingroff A, Arthington-Skaggs B, Iqbal N, Ellis D, Pfaller MA, Messer S, et al. Multicenter evaluation of a new disk agar diffusion method for susceptibility testing of filamentous fungi with voriconazole, posaconazole, itraconazole, amphotericin B, and caspofungin. J Clin Microbiol. 2007;45(6):1811-20. doi: 10.1128/JCM.00134-07. [PubMed: 17428932]. [PubMed Central: PMC1933077].
  • 10. Lass-Florl C. In vitro susceptibility testing in Aspergillus species: an update. Future Microbiol. 2010;5(5):789-99. doi: 10.2217/fmb.10.34. [PubMed: 20441550].
  • 11. Espinel-Ingroff A, Diekema DJ, Fothergill A, Johnson E, Pelaez T, Pfaller MA, et al. Wild-type MIC distributions and epidemiological cutoff values for the triazoles and six Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document). J Clin Microbiol. 2010;48(9):3251-7. doi: 10.1128/JCM.00536-10. [PubMed: 20592159]. [PubMed Central: PMC2937688].
  • 12. Espinel-Ingroff A, Fothergill A, Fuller J, Johnson E, Pelaez T, Turnidge J. Wild-type MIC distributions and epidemiological cutoff values for caspofungin and Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document). Antimicrob Agents Chemother. 2011;55(6):2855-9. doi: 10.1128/AAC.01730-10. [PubMed: 21422219]. [PubMed Central: PMC3101428].
  • 13. Espinel-Ingroff A, Canton E, Fothergill A, Ghannoum M, Johnson E, Jones RN, et al. Quality control guidelines for amphotericin B, Itraconazole, posaconazole, and voriconazole disk diffusion susceptibility tests with nonsupplemented Mueller-Hinton Agar (CLSI M51-A document) for nondermatophyte Filamentous Fungi. J Clin Microbiol. 2011;49(7):2568-71. doi: 10.1128/JCM.00393-11. [PubMed: 21543581]. [PubMed Central: PMC3147863].
  • 14. Diaz-Guerra TM, Mellado E, Cuenca-Estrella M, Rodriguez-Tudela JL. A point mutation in the 14alpha-sterol demethylase gene cyp51A contributes to itraconazole resistance in Aspergillus fumigatus. Antimicrob Agents Chemother. 2003;47(3):1120-4. [PubMed: 12604551]. [PubMed Central: PMC149335].
  • 15. Dalhoff A, Ambrose PG, Mouton JW. A long journey from minimum inhibitory concentration testing to clinically predictive breakpoints: deterministic and probabilistic approaches in deriving breakpoints. Infection. 2009;37(4):296-305. doi: 10.1007/s15010-009-7108-9. [PubMed: 19629383].
  • 16. Richardson M, Lass-Florl C. Changing epidemiology of systemic fungal infections. Clin Microbiol Infect. 2008;14 Suppl 4:5-24. doi: 10.1111/j.1469-0691.2008.01978.x. [PubMed: 18430126].
  • 17. Denning DW. Invasive aspergillosis in immunocompromised patients. Curr Opin Infect Dis. 1994;7(4):456-62. doi: 10.1097/00001432-199408000-00007.
  • 18. Lass-Florl C, Griff K, Mayr A, Petzer A, Gastl G, Bonatti H, et al. Epidemiology and outcome of infections due to Aspergillus terreus: 10-year single centre experience. Br J Haematol. 2005;131(2):201-7. doi: 10.1111/j.1365-2141.2005.05763.x. [PubMed: 16197450].
  • 19. Hedayati MT, Pasqualotto AC, Warn PA, Bowyer P, Denning DW. Aspergillus flavus: human pathogen, allergen and mycotoxin producer. Microbiology. 2007;153(Pt 6):1677-92. doi: 10.1099/mic.0.2007/007641-0. [PubMed: 17526826].
  • 20. Serrano MC, Ramirez M, Morilla D, Valverde A, Chavez M, Espinel-Ingroff A, et al. A comparative study of the disc diffusion method with the broth microdilution and Etest methods for voriconazole susceptibility testing of Aspergillus spp. J Antimicrob Chemother. 2004;53(5):739-42. doi: 10.1093/jac/dkh172. [PubMed: 15056643].
  • 21. Badiee P, Alborzi A, Moeini M, Haddadi P, Farshad S, Japoni A, et al. Antifungal susceptibility of the aspergillus species by Etest and CLSI reference methods. Arch Iran Med. 2012;15(7):429-32. [PubMed: 22724880].
  • 22. Hadrich I, Makni F, Neji S, Cheikhrouhou F, Bellaaj H, Elloumi M, et al. Amphotericin B in vitro resistance is associated with fatal Aspergillus flavus infection. Med Mycol. 2012;50(8):829-34. doi: 10.3109/13693786.2012.684154. [PubMed: 22587728].

Featured Image:

Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments